The Myeloproliferative Neoplasm-Symptom Assessment Form Total Symptom Score (MPN-SAF TSS); is a 10-item instrument designed to monitor the clinically relevant symptoms among patients with MPNs. The tool records the patient’s assessment of the incidence and severity of the symptoms given below.
Fatigue | Night sweats |
Early satiety | Itching |
Abdominal discomfort | Bone pain |
Inactivity | Fever |
Concentration problems | Weight loss |
The tool can be used to provide a fast, accurate assessment of symptoms associated with MPNs, track symptoms over time, and guide subsequent management decisions.
How to do it >> You need to select most appropriate level of your symptom by using slider on a scale from 0-10 by using slider button given below for each Q.
Score 0 means - absent/no such issue and Score 10 means worst imaginable/as bad as it can be
All 10 Q must be answered between 0-10
Refresh Page for recalculating the score !
The Myeloproliferative Neoplasm-Symptom Assessment Form Total Symptom Score (MPN-SAF TSS); is a 10-item instrument designed to monitor the clinically relevant symptoms among patients with MPNs. The tool records the patient’s assessment of the incidence and severity of the symptoms given below.
Fatigue | Night sweats |
Early satiety | Itching |
Abdominal discomfort | Bone pain |
Inactivity | Fever |
Concentration problems | Weight loss |
The tool can be used to provide a fast, accurate assessment of symptoms associated with MPNs, track symptoms over time, and guide subsequent management decisions.
QOL scores were defined as “clinically deficient” if scores were rated as at least 4 of 10 on a 0-to-10 scoring system.
In addition, MPN-SAF TSS items were designated as “moderate” if symptoms were rated as ≥ 4 of 10 or ≤ 6 of 10 and as “severe” if symptoms were rated as ≥ 7 of 10.
The MPN-SAF TSS has possible range of 0 to 100.
References
Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs
J Clin Oncol. 2012 Nov 20;30(33):4098-103. doi: 10.1200/JCO.2012.42.3863.